- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- GLAXOSMITHKLINE PHARMACEUTICALS LTD. (pharmaceuticals)
- Latest 8 Quarter Result
GSK Pharma Quarterly Results 
(GLXO)
Here are the latest quarterly results of GSK Pharma. For more details, see the GSK Pharma financial fact sheet and GSK Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
GSK Pharma Quarterly Results
| No. of Mths Qtr. Ending |
3
Sep-16 |
3
Dec-16 |
3
Mar-17* |
3
Jun-17 |
3
Sep-17 |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 7,991 | 7,064 | 7,837 | 6,071 | 8,363 | 7,039 | 7,486 | 7,357 | |
| Other income | Rs m | 181 | 148 | 149 | 137 | 96 | 120 | 183 | 178 | |
| Turnover | Rs m | 8,172 | 7,212 | 7,986 | 6,208 | 8,459 | 7,159 | 7,669 | 7,534 | |
| Expenses | Rs m | 6,582 | 6,364 | 6,469 | 5,874 | 6,442 | 5,621 | 5,938 | 5,953 | |
| Gross profit | Rs m | 1,409 | 700 | 1,626 | 323 | 1,973 | 1,418 | 1,549 | 1,321 | |
| Depreciation | Rs m | 66 | 66 | 78 | 75 | 77 | 134 | 94 | 114 | |
| Interest | Rs m | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | |
| Profit before tax | Rs m | 1,524 | 782 | 1,697 | 385 | 1,991 | 1,404 | 1,636 | 1,383 | |
| Tax | Rs m | 536 | 252 | 570 | 120 | 688 | 507 | 581 | 497 | |
| Profit after tax | Rs m | 989 | 530 | 1,127 | 264 | 1,303 | 897 | 1,056 | 886 | |
| Gross profit margin | % | 17.6 | 9.9 | 20.7 | 5.3 | 23.6 | 20.1 | 20.7 | 18.0 | |
| Effective tax rate | % | 35.1 | 32.3 | 33.6 | 31.3 | 34.6 | 36.1 | 35.5 | 35.9 | |
| Net profit margin | % | 12.4 | 7.5 | 14.4 | 4.4 | 15.6 | 12.7 | 14.1 | 12.0 | |
| Diluted EPS | Rs | 11.7 | 6.3 | 13.3 | 3.1 | 15.4 | 10.6 | 12.5 | 10.5 | |
| Diluted EPS (TTM) | Rs | 42.1 | 39.0 | 39.8 | 34.3 | 38.1 | 42.4 | 41.6 | 48.9 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: GSK Pharma 1QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: MERCK LTD INDRAPRASTHA MEDICAL CIPLA PFIZER INDOCO REMEDIES
Compare GSK PHARMA With: MERCK LTD INDRAPRASTHA MEDICAL CIPLA PFIZER INDOCO REMEDIES
Compare GSK PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex, Nifty Close at Record Highs; Energy and Metal Stocks Witness Buying(Closing)
Indian share markets continued their momentum during closing hours of trade and ended the day at their fresh record high levels.
Views on news
DIVIS LABORATORIES at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)
Aug 20, 2018 | Updated on Aug 20, 2018DIVIS LABORATORIES share price has hit a 52-week high. It is presently trading at Rs 1,224. BSE 500 Index is up by 0.5% at 15,582. Within the BSE 500, DIVIS LABORATORIES (up 4.3%) and KWALITY DAIRY (up 5.0%) are among the top gainers, while top losers are TECHNO ELECTRIC and RAIN INDUSTRIES.
GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)
Jul 26, 2018 | Updated on Jul 26, 2018For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)
May 28, 2018 | Updated on May 28, 2018For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)
Aug 8, 2018Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why
Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)
Aug 9, 2018Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...
Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)
Aug 16, 2018While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.
Why HDFC Equity Fund Disappointed Its Investors(Outside View)
Aug 9, 2018Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.
HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)
Aug 8, 2018PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.
More|
| |
GSK PHARMA SHARE PRICE
Aug 20, 2018 (Close)
TRACK GSK PHARMA
- Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK PHARMA
GSK PHARMA - MYLAN COMPARISON
COMPARE GSK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.